While early 2023 saw COVID-19 finally fading away, other global crises continued throughout the year (Russia-Ukraine invasion) or were newly created (Israel-Hamas conflict). In short, the socioeconomic environment remained turbulent.
2023-2024 Global Biopharma R&D Productivity And Growth Ranking
Industry R&D Productivity Driven By Mega Trends – From COVID-19 To Obesity
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
